# Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma

> **NCT03437070** · PHASE1 · WITHDRAWN · sponsor: **University of Miami**

## Conditions studied

- Leiomyosarcoma

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Doxorubicin
- **DRUG:** Olaratumab

## Key facts

- **NCT ID:** NCT03437070
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06
- **Primary completion:** 2021-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2019-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437070, "Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03437070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*